Since the FDA approval of anti-CTLA4 and anti-PD1 therapy for advanced melanoma in 2011 and 2015, respectively, ICI alone or in combination with other therapies have transformed the therapeutic landscape of nearly all solid tumors (18). The gene discussed is PDCD1; the disease is melanoma.